Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Report Code: BIO139B

Publish Date: Jul 2024

Publisher: BCC Publishing

Category: Cell Biology

Download Report Overview

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for single nucleotide polymorphism (SNP) is expected to grow from $32.0 billion in 2024 and is projected to reach $85.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 21.7% during the forecast period of 2024 to 2029.

Report Includes

  • 37 data tables and 44 additional tables
  • An overview of the global market for single nucleotide polymorphism (SNP) genotyping
  • Analyses of global market trends, with data from 2021-2023, estimates for 2024, and projected CAGRs through 2029
  • Evaluation of the current market size and revenue growth prospects specific to SNP genotyping, along with a market share analysis by technology, application, and region
  • Discussion of the advantages of the most frequently used SNP genotyping techniques, such as Sequenom’s MassArray DNA analysis platform, Bruker’s MALDI-TOF array, SNP pyrosequencing, microarrays and gene chips, and Applied Biosystems’ (now part of Thermo Fisher Scientific) SNPlex and TaqMan
  • Analysis of the regulatory framework and policies affecting the industry
  • Discussion of the ESG practices of, as well as challenges for, companies
  • Analysis of the key companies’ market shares and their proprietary technologies, strategic alliances and patents
  • Company profiles of the leading players, including Agilent Technologies Inc., F. Hoffman-La Roche Ltd., Illumina Inc., Qiagen, and Thermo Fisher Scientific Inc.

Report Scope

This report covers the worldwide market for SNP genotyping, with the market segmented by technology and application. It provides an in-depth analysis of the SNP genotyping market, including estimates and trends through 2029. In this report, the market is divided into four regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. This report also uses analytical frameworks such as PESTEL, examines the competitive landscape, and explores trends in ESG and funding.

Report Synopsis

Report Metrics Details
Base year considered 2023
Forecast period considered 2024-2029
Base year market size $26.4 billion
Market size forecast $85.5 billion
Growth rate CAGR of 21.7% for the forecast period of 2024-2029
Units considered $ Millions
Segments covered Technology, Application, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers
  • Declining prices of DNA sequencing methods.
  • Demand for personalized treatments, driven by the rising prevalence of cancer and cardiovascular diseases.
  • Increasing demand for SNP genotyping in the drug development process.
Companies studied
BECKMAN COULTER INC. (SUBSIDIARY OF DANAHER CORP.)QIAGEN
STANDARD BIOTOOLSTHERMO FISHER SCIENTIFIC INC.
AGILENT TECHNOLOGIES INC.BIO-RAD LABORATORIES INC.
CYTIVAENZO BIOCHEM INC.
EPIGENDXF. HOFFMANN-LA ROCHE LTD.
ILLUMINA INC.
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The global SNP genotyping market is valued at an estimated $32.0 billion in 2024 and is projected to reach $85.5 billion by 2029, at an estimated CAGR of 21.7% during the forecast period of 2024 to 2029.
  • Decline in the prices of DNA sequencing methods.
  • Growing prevalence of cancer, cardiovascular diseases propelling demand for personalized treatments.
  • Increasing demand for SNP genotyping in drug development process.
The report will provide information on SNP genotyping along with their growth projections in the coming years. Recent developments of companies operating in this market space have been covered. Information about technologies, applications, PESTEL analysis, funding scenario, and business strategies have been provided in the report. The report also identifies promising and emerging countries where the established players can plausibly expand their business.
The microarrays and geneChips segment dominates the overall SNP genotyping market and will continue to do so by 2029.
North America holds the highest share in the market.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets110Free
Chapter- 1: Executive Summary4Free
Chapter- 2: Market Overview6Free
Chapter- 3: Market Dynamics6Free
Chapter- 4: Emerging Technologies and Developments3Free
Chapter- 5: Market Segmentation Analysis41Free
Chapter- 6: Competitive Intelligence8Free
Chapter- 7: Sustainability in the SNP Genotyping Market: An ESG Perspective7Free
Chapter- 8: Appendix35Free
Published - Sep-2014| Analyst - Vijay Laxmi| Code - BIO139A

Report Highlights

The global single nucleotide polymorphism (SNP) genotyping market was valued at $3.5 billion in 2013. This market is expected to reach $4.3 billion in 2014 and $11.5 billion in 2019, a compound annual growth rate (CAGR) of 21.9% from 2014 to 2019.

Report Includes

  • An overview of the global markets for single nucleotide polymorphism genotyping.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of CAGRs through 2019.
  • A geographic breakdown into the regions of North America, Europe, Asia-Pacific (APAC), and the rest of the world.
  • Information on the market's dynamics as well as innovations and current trends.
  • Analysis of the regulatory environment and its impact.
  • Evaluation of market drivers, restraints, and opportunities.
  • Relevant patent analysis.

Related Reports

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Published - Feb 2024 | Publisher - BCC Publishing | Code - BIO126E

The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.

Polymerase Chain Reaction (PCR) Technologies and Global Markets

Published - Jan 2024 | Publisher - BCC Publishing | Code - BIO087E

The global market for polymerase chain reaction (PCR) is estimated to increase from $9.1 billion in 2023 to reach $12.6 billion by 2028, at a compound annual growth rate (CAGR) of 6.7% from 2023 through 2028.

Digital Polymerase Chain Reaction (dPCR) Technology: Global Markets

Published - Nov 2023 | Publisher - BCC Publishing | Code - BIO137C

The global market for digital polymerase chain reaction (dPCR) technology is expected to grow from $752.1 million in 2023 to $1.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023-2028.

Recent Reports

Bioprocess Optimization and Digital Bio-manufacturing: Global Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO170B

The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets
Sample Report